GE HealthCare Securities Fraud Investigation
Analysis based on 27 articles · First reported Jul 07, 2026 · Last updated Jul 31, 2026
The investigation and the underlying earnings miss and guidance cut have negatively impacted GE HealthCare's stock price, which fell 13.2% on the day of the announcement. The ongoing investigation and CFO departure may further pressure the stock and raise concerns about corporate governance and financial reporting.
Multiple law firms, including Glancy Prongay & Murray LLP, the Law Offices of Frank R. Cruz, and the Law Offices of Howard G. Smith, are investigating GE HealthCare Technologies Inc. for possible violations of federal securities laws. The investigation stems from GE HealthCare's first-quarter 2026 earnings report on April 29, 2026, in which the company reported adjusted EPS of $0.99 and cut its full-year 2026 adjusted EPS guidance to $4.80-$5.00 from $4.95-$5.15. Management attributed the shortfall to a recall associated with a PDx supplier and declines in PCS. Following the announcement, GE HealthCare's stock fell 13.2% to $59.49. Additionally, on July 23, 2026, the company announced that CFO Jay Saccaro would step down, with an interim CFO to be appointed. The law firms are urging investors who lost money to contact them to potentially pursue claims.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard